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A prospective study was conducted to determine if standardized vancomycin doses could produce adequate serum concentrations
in 25 term newborn infants with sepsis. Purpose: The therapeutic response of neonatal sepsis by Staphylococcus sp. treated with
vancomycin was evaluated through serum concentrations of vancomycin, serum bactericidal titers (SBT), and minimum inhibitory
concentration (MIC).
Method: Vancomycin serum concentrations were determined by the fluorescence polarization immunoassay technique , SBT
by the macro-broth dilution method, and MIC by diffusion test in agar .
Results: Thirteen newborn infants (59.1%) had adequate peak vancomycin serum concentrations (20–40 mg/mL) and one had
peak concentration with potential ototoxicity risk (>40 µg/mL). Only 48% had adequate trough concentrations (5–10 mg/mL), and
seven (28%) had a potential nephrotoxicity risk (>10 µg/mL). There was no significant agreement regarding normality for peak and
trough vancomycin method (McNemar test : p = 0.7905). Peak serum vancomycin concentrations were compared with the clinical
evaluation (good or bad clinical evolution) of the infants, with no significant difference found (U=51.5; p=0.1947). There was also
no significant difference between the patients’ trough concentrations and good or bad clinical evolution (U = 77.0; p=0.1710). All
Staphylococcus isolates were sensitive to vancomycin according to the MIC. Half of the patients with adequate trough SBT (1/8),
also had adequate trough vancomycin concentrations and satisfactory clinical evolution.
Conclusions: Recommended vancomycin schedules for term newborn infants with neonatal sepsis should be based on the
weight and postconceptual age only to start antimicrobial therapy.  There is no ideal pattern of vancomycin dosing; vancomycin
dosages must be individualized. SBT interpretation should be made in conjunction with the patient’s clinical presentation and
vancomycin serum concentrations. Those laboratory and clinical data favor elucidation of the probable cause of patient’s bad
evolution, which would facilitate drug adjustment and reduce the risk of toxicity or failing to achieve therapeutic doses.
DESCRIPTORS: Physiologic monitoring. Newborn infants. Sepsis. Vancomycin. Antimicrobial susceptibility testing.
Since 1990 Staphylococcus sp., or,
more precisely, the coagulase-negative
Staphylococcus, has been the pathogen
most commonly associated with hospi-
tal-acquired infection in neonatal inten-
sive-care units of several countries.
Until the end of the 80’s coagulase-
negative Staphylococcus was consid-
ered to be non-pathogenic1-5.
There is an array of difficulties in
the therapy of newborns severely in-
fected by Staphylococcus sp., the most
prominent of which are the indication
of antibiotic therapy, the prescribed
dose, and length of its use. Therapeu-
tic failure is due to many factors that
are hardly ever measurable; such as the
newborn’s humoral and cellular de-
fenses, site and severity of the infec-
tion, the virulence of the strain, quan-
tity of bacteria present, and the varia-
tion of serum concentrations of antimi-
crobial agents in vivo6,7,8. In addition,
the symptoms of neonatal sepsis are
discrete and/or non-specific, and in-
clude thermal disturbances (hypo or
hyperthermia), respiratory distress (ta-
chypnea, grunting, apnea), cyanosis,
tachycardia, poor feeding, postprandial
gastric residue, or abdominal disten-
tion9.
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The associations and changes of
antibiotics, when empirically made
without taking into account the
patient’s response, or especially, the
etiologic agent, often lead to super-in-
fections by multi-resistant bacteria and
fungi.
As a result, the increased incidence
of nosocomial infections by methicil-
lin-resistant Staphylococcus sp. in neo-
natal intensive care units has led to an
increase in the utilization of vancomy-
cin. Its widespread use, however, has
brought about the emergence of Sta-
phylococcus sp, which is increasingly
resistant to this drug.
To obtain success with antimicro-
bial therapy, it is necessary to select the
appropriate antibiotic and provide the
adequate dose, as well as to use the
best administration technique. With the
introduction of studies characterizing
the parameters of antibiotic pharmaco-
kinetics in specific populations, the
usual dose of vancomycin has been
demonstrated to be either insufficient
or potentially toxic in many situa-
tions10,11. In this context, monitoring of
both the antibiotic therapy and the
newborn’s clinical response becomes
significantly important. Therefore, the
authors’ purpose was to assess whether
therapy with vancomycin results in ad-
equate serum concentrations of the an-
tibiotic in term neonates with sepsis
and to evaluate the antimicrobial
therapy of neonatal sepsis caused by
Staphylococcus sp., monitoring the se-
rum vancomycin concentration, serum
bactericidal titers (SBT), and minimum
inhibitory concentration (MIC).
METHOD
The study population consisted of
25 term newborns admitted to the
Outpatient Newborn Intensive Care
Unit (ONICU), during the period from
October 1995 to October 1997, with
diagnoses of neonatal sepsis, all of
whom received vancomycin after ad-
mission to the ONICU.
The diagnostic criteria of neonatal
sepsis were based on clinical signs12,
hypothermia or hyperthermia, respira-
tory alterations (tachypnea, grunting,
apnea), cyanosis, tachycardia, poor
feeding, postprandial gastric residue, or
abdominal distention.
This was a prospective study, in
which the authors included term new-
borns with gestational ages of > 37 and
< 42 weeks, based on the date of the
mother’s last menstrual period, with
clinical and laboratory diagnoses of
neonatal sepsis and suspicion of noso-
comial infection caused by Staphylo-
coccus sp.
All patients included in the sample
received oxacillin and/or amino-
glucosides in other services previous to
the introduction of vancomycin. None
of the patients included in this study
presented kidney failure at the onset of
treatment with vancomycin. Initially,
the newborns also received antibiotic
therapy for gram-negative bacteria un-
til elucidation of the etiologic agent by
means of blood culture or general cul-
tures.
The term newborn infants with sep-
sis who had vancomycin suspended
before completing 14 days of antibiotic
therapy were excluded from the study.
The vancomycin dose adminis-
trated and intervals of administration
were established according to post-
conceptual age13, based on the routine
of the ONICU  (Table 1).
The BACTEC automated system
was used to identify the infectious
agent in the blood cultures. Vancomy-
cin (VancocynÒ/Lilly) was diluted in
dextrose solution at 5% (D5W) and ad-
ministered intravenously with an infu-
sion pump over a period of 1 hour into
a peripheral vein or central catheter.
After 72 hours of antibiotic therapy
with vancomycin, 0.8 mL blood
samples were collected 1 hour after the
end of infusion (serum peak) for dos-
ing serum vancomycin concentration by
the fluorescence polarization immu-
noassay technique (TDx/Abbott). The
same procedure was performed with the
sample collected 1 hour before the be-
ginning of the next vancomycin dose,
i.e. at the serum trough. The authors
considered as normal or adequate val-
ues for peak serum concentration of
vancomycin 20 to 40 mg/mL and
trough concentration 5 to 10 mg/mL14,15.
For newborn infants who had
Staphylococcus sp. isolated, the serum
bactericidal titer (SBT) was also mea-
sured, both at the serum peak and
trough, by the macro-broth dilution
method. Trough SBT 1/8 and peak
SBT 1/16, at the minimum, were con-
sidered adequate16,17.
In addition, the minimum inhibi-
tory concentration (MIC) of vancomy-
cin was analyzed in those that had Sta-
phylococcus sp. isolated. The E-testÒ
(AB-Biodisk), consisting of micro-dif-
fusion test in agar, was the technique
used to obtain the MIC of vancomycin.
According to the criteria adopted by
Table 1 -  Vancomycin dosing  regimens for newborn infants13.
Post-conceptual   age (weeks) (mg/Kg/dose) Interval (hours)
 29 20 24
30 - 33 20 18
34 -37 20 12
38 - 44 15 8
 45 10 6
	
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the National Committee for Clinical
Laboratory Standard (NCCLS)18-22, an
MIC < 4 mg/mL was considered as
susceptible, a MIC of 8 to 16 mg/mL
as intermediate, and over 32 mg/mL23
as resistant.
With the objective of diagnosing
nephrotoxicity, serum urea and creati-
nine were collected at the onset of
treatment and 5 days after it, in accor-
dance with the routine of the Service
for dosing by automated method
(COBAS). The values considered nor-
mal were from 5 to 35 mg/dL for se-
rum urea and from 0.4 of 0.96 mg/%
for serum creatinine24,25.
With regard to treatment, the pro-
gressive disappearance of clinical signs
of sepsis, according to Bone’s criteria12,
was considered good clinical evolution,
and the permanence or worsening of
clinical signs of sepsis after at least 72
hours of treatment with vancomycin
was considered bad clinical evolution.
When needed, patients underwent
clinical intervention involving increase
or decrease of vancomycin dosage, in-
crease or decrease of the intervals be-
tween administrations, or the supply of
immunotherapeutic support (plasma
and immunoglobulins).
The variables studied — gestational
age, post-conceptual age, patient’s
weight at birth and at the moment of
collection, and peak and trough serum
concentration of vancomycin — were
analyzed by descriptive methods.
The McNemar test was performed
to evaluate whether trough and peak
normality levels were equivalent.
The clinical evolution variable split
the sample into 2 groups, one with bad
evolution and another with good evo-
lution. The 2 groups of clinical evolu-
tion were compared with regard to the
serum concentrations of vancomycin,
as well as to the numeric variable
(Mann-Whitney’s statistical U test).
The pre- and post-vancomycin admin-
istration dosages of serum urea and
creatinine were evaluated by
Wilcoxon’s Z Test. The authors estab-
lished an a error of 5%.
RESULTS
The gestational age of the newborn
infants included in this study varied
from 37 weeks to 41 weeks and 5 days,
and the post-conceptual age from 38
weeks to 44 weeks and 5 days. The av-
erage gestational age was 38 weeks ±
1 week; median of 39 weeks, while the
average post-conceptual age was 41
weeks ± 2 weeks, median of 41 weeks.
At the time of collection, the aver-
age weight was 3130 g ± 861.3, me-
dian of 3000 g. In 9 (36%) of the cases,
the cultures were positive for Staphy-
lococcus sp., 88.9% of which were Sta-
phylococcus coagulase-negative and
11.1% were Staphylococcus aureus
positive.
With regard to the susceptibility
shown by the minimum inhibitory con-
centration (MIC), all the strains were
sensitive to vancomycin in vitro, since
the MIC varied from 1.0 to 3.0 mg/mL
(Table 2).
In the 25 cases studied here, 22
samples were collected at the serum
peak and 25 at the serum trough of
vancomycin.
Serum vancomycin levels obtained
at the serum peak of vancomycin var-
ied from 5.1 to 51 mg/mL, with an av-
erage of 23.9 ± 10.8 and median of
25.5, while those levels at the serum
trough varied from 2.6 to 25 mg/mL,
with average of 9.4 ± 5.8 and median
of 8.0.
Thirteen cases (59.1%) presented
adequate or normal peak serum con-
centrations of vancomycin.
There were 8 cases (36.4%) with
peak serum concentrations of vanco-
mycin below 20 mg/mL, while just
4.5% of the cases presented a serum
concentration of vancomycin with po-
tential risk for ototoxicity, i.e. with
peaks above 40 mg/mL.
With regard to concentrations at the
serum trough of vancomycin, the low-
est value obtained was 2.6 mg/mL, and
25.0 mg/mL was the highest. The aver-
age was 9.4 mg/mL ± 5.8 and the me-
dian 8 mg/mL. Nineteen cases (76%)
presented therapeutic serum levels of
vancomycin. Just 12 cases (48%), how-
ever, presented adequate or normal se-
rum values at the trough. Sub-therapeu-
tic levels (serum concentrations of van-
comycin at the valley below 5 mg/mL)
were found in 6 cases (24%). In 7 of the
cases (28%), there were serum concen-
trations above 10 mg/mL, with poten-
tial risk of nephrotoxicity.
Only 5 cases (22.7%) presented ad-
equate peak and trough serum concen-
trations of vancomycin. There was,
therefore, no significant agreement be-
tween normality (adequate results) de-
termined by peak and trough of van-
comycin in the evaluation by the TDx/
Abbottâ method (McNemar’s Test: p =
0.7905 (Table 3).
Wilcoxon’s Z Test was used to
compare the serum levels of urea and
Table 2 - Cases with positive culture.
Cases Infectious Agent MIC (mg/mL)
1 S. coagulase negative 1.5
2 Staphylococcus haemolyticus 1.0
4 S. coagulase negative 1.0
7 S. coagulase negative 2.0
17 S. coagulase negative 3.0
18 S. coagulase negative 1.0
20 S. coagulase negative 1.5
21 S. coagulase negative 1.5
25 Staphylococcus aureus 1.5

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creatinine before and after the admin-
istration of vancomycin. The results
showed that the difference between the
values of serum urea pre- and post-van-
comycin was not statistically signifi-
cant: Z = 1.02; p = 0.3062. Conversely,
the difference between the values of
serum creatinine, before and after the
introduction of vancomycin was statis-
tically significant: Z = 2.54; p =
0.0444.
The authors compared peak serum
concentration of vancomycin to the
clinical evolution of the newborn in-
fants with sepsis, using Mann-
Whitney’s U Test. There was no statis-
tically significant difference between
the values of serum peaks obtained
from those with good or bad evolution:
U=51.5; p=0.1947. (Table 4).
In addition, there was also no statis-
tically significant difference between the
values of serum valleys obtained from
those with good or bad clinical evolu-
tion: U= 77.0);  p=0.1710. (Table 5).
It was possible to determine the se-
rum bactericidal titers (SBT) in 6 of the
patients that presented Staphylococcus
sp-positive blood or general cultures.
The SBT was not determined in all of
the cases, due to flaws in collection and
in the  macro-broth dilution technique.
Of the 6 determinations performed at
both the peak and trough levels of se-
rum vancomycin, 3 cases (50%) pre-
sented adequate SBT at both peak and
trough conditions.
The data regarding laboratory and
clinical monitoring is presented in table 6.
DISCUSSION
The few published prospective
studies on neonatology or pharmacol-
ogy dealing with the levels of serum
concentrations of vancomycin mostly
report results obtained from preterm
newborn infants (30 to 36 weeks of
post-conceptual age). Due to the small
number of cases studied to date world-
Table 6 - Comparison of  therapeutic serum concentration  (mg/ml). trough sbt
(titer), mic (mg/ml), and clinical evolution in each case.
Cases Trough Serum MIC TROUGH Evolution
concentration (g/mL) SBT
(g/mL)
1 25.0 1.5 1/16 Good
2 5.0 1.0 1/16 Good
4 4.2 1.0 1/4 Bad
7 8.0 2.0 1/2 Good
17 12.2 3.0 1/4 Good
18 9.3 1.0 1/8 Good
20 2.7 1.5 - Bad
21 5.5 1.5 - Good
25 6.4 1.5 - Bad (death)
Table 5 - Comparison of  trough serum concentration of vancomycin  (mg/ml) to
the newborn infants’ clinical evolution with sepsis.
Clinical Evolution
3rd to 4th day of Average ± SD Median Minimum Maximum
antibiotic therapy
Good   (n= 20) 10.2  ± 5.8 8.8 4.5 25.0
Bad    (n = 5) 6.2  ± 5.2 4.2 2.6 15.0
U = 77.0 p = 0.1710
Table 4 - Comparison of  peak serum concentration of vancomycin  (mg/ml) to
the newborn infants’ clinical evolution with sepsis.
Clinical Evolution
3rd to 4th day of Average ± SD Median Minimum Maximum
antibiotic therapy
Good  (n= 18) 25.2  ± 10.7 27.4 5.1 51.0
Bad   (n = 4) 18.1  ± 10.6 16.4 8.8 31.0
U = 51.5 p = 0.1947
Table 3 -  Agreement between normality determined by the peak serum
concentrations  (20-40 mg/ml) and at the trough (5-10 mg/ml) as measured by
TDx/Abbott® method.
Peak
Valley Adequate (%) Inadequate (%) Total (%)
Adequate 5 (22.73) 6 (27.27) 11 (50)
Inadequate 8 (36.36) 3 (13.64) 11 (50)
Total 13 (59.09) 9 (40.91) 22 (100)
McNemar’s Test: P = 0.7905
wide, further studies in term newborns
are needed 26.
The authors determined vancomy-
cin levels by the fluorescence polariza-
tion immunoassay procedure (TDx/
Abbott). It was employed because it
is still the technique used most inter-
nationally; among its advantages are
the possibility of quick analysis, the
requirement for small amounts of se-
rum samples, and its low cost.
The pharmacokinetic profile of

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vancomycin is best described by a 2 or
3 compartmental model, and it is be-
lieved that a compartmental model is
adequate to describe it in the clinical
practice26. A single compartmental
model has also been used in recent
studies of the pharmacokinetics of van-
comycin in premature infants. Al-
though there may be shortcomings in
the use of the single compartmental
model, it is believed that these are not
clinically significant 27-32.
To determine the peak serum con-
centration, a sample was collected 1
hour after the end of the infusion, in
order to minimize the effect of incom-
plete distribution of the drug33-35.
Some authors have shown greater
percentages of adequate peak serum
than those found in the present study,
reaching as much as 92%, with peak
serum concentrations of vancomycin
between 20 – 40 mg/mL. These results,
however, vary greatly in the literature,
and most of them are from preterm in-
fants36.
When the serum concentration of
vancomycin is collected at the peak,
the objective is to diagnose the poten-
tial risk for ototoxicity, although there
is limited information in the literature
regarding this possible toxic effect re-
lated to vancomycin in newborns27 .
When the serum content of vanco-
mycin is collected at the trough, the
goal is to detect the nephrotoxic ef-
fects, as well as the adequate or sub-
therapeutic serum concentrations.
Some authors14 consider the serum
level as therapeutic when the concen-
tration at the valley is > 5 mg/mL.
Thus, the therapeutic serum level of
vancomycin is adequate when it is > 5
and £ 10 mg/mL, or inadequate when
it is above 10 mg/mL (therapeutic, but
with potential risk for nephrotoxicity).
The adequate serum concentrations
of vancomycin at the valley and at the
peak in pediatric patients vary between
5 and 12 and between 25 and 40 mg/
mL, respectively. Other authors, as
mentioned previously, consider as ad-
equate the serum valleys of vancomy-
cin between 5 and 10 mg/mL and the
serum peaks between 20 – 40 mg/
mL14.
The nephrotoxicity due to vanco-
mycin is associated to trough serum
concentrations above 30 mg/mL27.
When the SBT value is obtained, it
is possible to correlate it to the serum
concentration value of the antibiotic.
Some authors suggest that there has
to be a minimum of 1/8 of trough se-
rum bactericidal titer for it is associated
to efficacy in the treatment26.
Other authors report the relation-
ship between SBT levels of 1/8 at the
serum trough and successful healing in
95% of the pediatric patients (with
ages varying from 3 days to 12
years)27. In our results, there was one
case in which it was necessary to main-
tain the serum concentration of vanco-
mycin above 12 mg/mL to obtain a
trough SBT of 1/8. The SBT can dem-
onstrate that the patient’s serum is act-
ing efficiently against the infection, but
that does not necessarily mean that
there is efficacy at the infection site.
Examples of sites in which this can oc-
cur are bones, cerebrospinalis fluid,
and pleural fluids, since the SBT mea-
sures the therapeutic action of the se-
rum against the bacteria in vitro, not at
the infection site.
With regard to clinical follow-up,
there are no studies with term infants
in the literature that analyze the direct
effect of concentrations of vancomycin
and patients’ clinical responses. There
are also few studies that correlate MIC,
SBT, and rates of cure14,37-39.
However, if the therapeutic objec-
tive is a 20 – 40 mg/mL range of peak
serum concentration of vancomycin,
that would result in peak serum values
20 times greater than the MIC and
trough values 5 to 8 times greater than
the MIC36.
By definition, if the trough serum
concentration of the antibiotic is 4 to
8 times greater than the MIC, it means
that the vancomycin has reached thera-
peutic tissue concentration.
Considering only the patients with
adequate peak serum vancomycin con-
centrations, the concentration varied
from 13 to 20.7 times the MIC; in the
patients with adequate trough serum
levels, the concentration varied from 4
to 9.3 times the MIC. The latter values
are close to those found in the existing
literature.
The lack of standardization of the
dosage or of concern for the individual
patient often results in undesirable
pharmacokinetic effects, which results
in the action of the drug being thera-
peutically ineffective.
Therapy with potent drugs becomes
safer and more effective in the neona-
tal period when the dose is adjusted to
the needs and tolerance of each new-
born, since there are individual differ-
ences regarding the bioavailability of
the dose used, host factors, weight and
general conditions of the patient, dis-
tribution through compartments and
fluids, links to inactive sites, metabo-
lizing rate, and renal excretion. All of
these determining factors undergo in-
dividual and temporal variations.
CONCLUSIONS
Recommended vancomycin doses
for term treatment of newborn infants
have to be based on individual weight
and especially on the post-conceptual
age. A standardized dose should be
used only to start the antimicrobial
therapy in cases of neonatal sepsis; the
dose must be individualized and cor-
rected after the measurement of the se-
rum level of vancomycin, which is the
indispensable requirement for correc-
tion of the antibiotic dose.
Kidney function must be monitored
before and during the administration of
vancomycin. In cases in which kidney
failure is observed, the first step is to

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RESUMO RHCFAP/3031
MACHADO JKK e col. - Monitori-
zação da terapêutica com vancomicina
em recém-nascidos de termo com
sepse, utilização e importância clínica.
Rev. Hosp. Clín. Fac. Med. S. Paulo
56(1):17-24, 2001.
Foi realizado um estudo pros-
pectivo para verificar se as doses ha-
bituais de vancomicina determinam
concentrações séricas adequadas em 25
recém - nascidos de  termo com sepse.
Objetivos: Avaliou-se a resposta
terapêutica da sepse neonatal por
Staphylococcus sp., tratada com
vancomicina, monitorizando além de
sua concentração sérica, o poder
bactericida do soro (PBS) e a concen-
tração inibitória mínima (MIC).
Método: Os níveis séricos do anti-
biótico foram obtidos através do
imunoensaio por fluorescência polari-
zada, o MIC através de micro-difusão
em ágar, e o PBS foi obtido por macro-
diluição em caldo.
Resultados: Concentrações séricas
no pico de vancomicina adequadas
(20-40 mg/mL) ocorreram em 59,1%
dos casos e um recém-nascido apresen-
tou potencial risco de ototoxicidade
(>40 mg/mL). Em 48% dos pacientes
ocorreram vales séricos adequados (5-
10 mg/mL) e 28% dos pacientes apre-
sentaram potencial risco de
nefrotoxicidade (>10mg/mL).  Não
houve concordância significante entre
a normalidade determinada pelo pico e
vale de vancomicina no método (pro-
va de McNemar: p=0,7905). A concen-
tração sérica no pico de vancomicina
foi comparada com a evolução clínica
dos recém-nascidos com sepse
neonatal, não havendo diferença esta-
tisticamente significante entre os picos
séricos dos pacientes que apresentaram
boa e má evolução (U=51,5;
p=0,1947). Também não houve dife-
rença estatisticamente  significante en-
tre os  vales séricos dos pacientes que
apresentaram boa e má evolução clíni-
ca ( U= 77,0; p=0,1710).  Todos os
MICs obtidos demonstraram sensibili-
dade à vancomicina. Metade dos paci-
entes que apresentou PBS no vale ade-
quado (1/8), também tiveram concen-
tração sérica de vancomicina adequa-
da e boa evolução clínica.
Conclusões: A recomendação de
doses de vancomicina para recém-nas-
cidos de termo deve ser baseada no peso
e na idade pós-conceptual apenas para
dar início à terapia antimicrobiana na
sepse neonatal, não existindo um padrão
de doses ideal. Logo, a dose deve ser
individualizada. A utilização desses da-
dos laboratoriais com a clínica favore-
cem a elucidação da provável causa da
má evolução do paciente, facilitando o
ajuste da droga e a menor chance de
efeitos tóxicos ou sub-terapêuticos .
DESCRITORES: Monitorização
fisiológica. Recém-nascido. Sepse.
Vancomicina. Teste de susceptibili-
dade antimicrobiana.
lengthen the intervals between the
doses of vancomycin to achieve a
lower frequency of administration
while maintaining the same vancomy-
cin concentration at the serum peak.
Although the study sample was
small, the authors concluded that the
SBT must be analyzed in conjunction
with the patient’s clinical evaluation
and the measurements of the serum
concentration values of vancomycin.
The MIC must always be part of the
antibiogram in order to quantify the
susceptibility of the Staphylococcus sp.
and to obtain the precise information
regarding the intermediate or the van-
comycin-resistant strains. The use of
these laboratory data in association
with clinical observations facilitates the
adjustment of the dose and decreases
the probability of toxic or sub-thera-
peutic effects, favoring the successful
treatment of the newborn.

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